Physician profile
Brian R Bennett
NPI 1477501609
$1,063.32
in general payments reported to CMS, 2019-2025
22 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $45.30 · 2021: $24.88 · 2022: $60.54 · 2023: $290 · 2024: $204 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $318.39 | 2019-2024 | Veozah |
| Abbvie INC. | $106.52 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $84.60 | 2019-2025 | |
| Glaxosmithkline, LLC. | $80.39 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $48.93 | 2025 | Gemtesa |
| Amgen INC. | $41.84 | 2020-2023 | Evenity, Prolia |
| Intuitive Surgical, INC. | $40.92 | 2024 | |
| Novo Nordisk INC | $37.25 | 2023 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $35.15 | 2019-2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $26.52 | 2023 | Unithroid |
| Acadia Pharmaceuticals INC | $26.45 | 2025 | Nuplazid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.67 | 2021-2023 | Jardiance |
| Lilly USA, LLC | $24.89 | 2020-2022 | |
| Abbott Laboratories | $24.19 | 2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $21.56 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.54 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.72 | 2019 | |
| Mannkind Corporation | $18.60 | 2023 | Afrezza |
| Scilex Pharmaceuticals INC. | $16.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.04 | 2022 | |
| Medtronic, INC. | $14.67 | 2023 | Clydesdale Ptc Spinal System |
| Merck Sharp & Dohme LLC | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.